High-dose oral CBD raised anandamide levels 1.6-fold, and adding THC boosted the effect to 2.1-fold
A single 800 mg oral CBD dose increased serum anandamide 1.6-fold in healthy volunteers, while combining CBD with THC produced a 2.1-fold increase, suggesting the two cannabinoids have synergistic effects on endocannabinoid signaling.
Quick Facts
What This Study Found
CBD at 800 mg (but not 600 mg) significantly increased serum anandamide (1.6-fold), OEA and PEA (1.4-fold). THC at 10 and 20 mg initially decreased anandamide but levels returned to baseline by 160 minutes. Combining CBD 800 mg + THC 20 mg produced the highest increases: anandamide 2.1-fold, OEA 1.9-fold, PEA 1.8-fold, without reaching a plateau.
Key Numbers
75 healthy volunteers. CBD 800 mg: anandamide +1.6-fold, OEA/PEA +1.4-fold. CBD 600 mg: no significant effect. THC 10 mg: anandamide -1.3-fold initially. CBD 800 + THC 20: anandamide +2.1-fold, OEA +1.9-fold, PEA +1.8-fold.
How They Did This
Two independent parallel-designed clinical trials with 75 healthy volunteers. Single oral doses of CBD (600 or 800 mg), THC (10 or 20 mg), or CBD+THC combination. Serum endocannabinoid levels measured by LC-MS/MS at baseline, 65, and 160 minutes post-administration.
Why This Research Matters
In schizophrenia trials, CBD doses of 800 mg+ showed clinical benefit, and anandamide elevation has been linked to improvement. This study confirms the dose threshold for anandamide elevation and reveals that THC combination enhances the effect, providing a pharmacological rationale for specific dosing.
The Bigger Picture
These findings provide a biological readout for CBD dosing in psychiatric treatment. The dose-dependent effect and the synergy with THC could help clinicians calibrate cannabinoid prescriptions for conditions where endocannabinoid signaling is relevant.
What This Study Doesn't Tell Us
Single-dose study in healthy volunteers; chronic dosing may differ. Only two CBD doses tested (600 vs. 800 mg). Serum levels may not reflect brain endocannabinoid changes. Short measurement window (160 minutes).
Questions This Raises
- ?Would even higher CBD doses produce greater anandamide increases?
- ?Does the CBD-THC synergy on anandamide translate to enhanced clinical outcomes?
- ?Is the 2.1-fold anandamide increase clinically meaningful for psychiatric conditions?
Trust & Context
- Key Stat:
- 2.1-fold anandamide increase with CBD + THC combination
- Evidence Grade:
- Two parallel-designed clinical trials with objective biomarker outcomes. Limited by single-dose design and healthy volunteer population.
- Study Age:
- Published in 2024 in BMJ Mental Health.
- Original Title:
- Dose-dependent effects of oral cannabidiol and delta-9-tetrahydrocannabinol on serum anandamide and related N-acylethanolamines in healthy volunteers.
- Published In:
- BMJ mental health, 27(1) (2024)
- Authors:
- Couttas, Timothy A, Boost, Carola, Pahlisch, Franziska(2), Sykorova, Eliska B, Mueller, Juliane K, Jieu, Beverly, Leweke, Judith E, Dammann, Inga, Hoffmann, Anna E, Loeffler, Martin, Grimm, Oliver, Enning, Frank, Flor, Herta, Meyer-Lindenberg, Andreas, Koethe, Dagmar, Rohleder, Cathrin, Leweke, F Markus
- Database ID:
- RTHC-05234
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
Does CBD raise endocannabinoid levels?
Yes, but only at higher doses. In this study, 800 mg CBD increased anandamide 1.6-fold while 600 mg had no significant effect, suggesting a dose threshold for this effect.
Does combining CBD and THC enhance the effect?
Yes. Combining 800 mg CBD with 20 mg THC produced the largest anandamide increase (2.1-fold), greater than either compound alone, suggesting synergistic effects on endocannabinoid signaling.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-05234APA
Couttas, Timothy A; Boost, Carola; Pahlisch, Franziska; Sykorova, Eliska B; Mueller, Juliane K; Jieu, Beverly; Leweke, Judith E; Dammann, Inga; Hoffmann, Anna E; Loeffler, Martin; Grimm, Oliver; Enning, Frank; Flor, Herta; Meyer-Lindenberg, Andreas; Koethe, Dagmar; Rohleder, Cathrin; Leweke, F Markus. (2024). Dose-dependent effects of oral cannabidiol and delta-9-tetrahydrocannabinol on serum anandamide and related N-acylethanolamines in healthy volunteers.. BMJ mental health, 27(1). https://doi.org/10.1136/bmjment-2024-301027
MLA
Couttas, Timothy A, et al. "Dose-dependent effects of oral cannabidiol and delta-9-tetrahydrocannabinol on serum anandamide and related N-acylethanolamines in healthy volunteers.." BMJ mental health, 2024. https://doi.org/10.1136/bmjment-2024-301027
RethinkTHC
RethinkTHC Research Database. "Dose-dependent effects of oral cannabidiol and delta-9-tetra..." RTHC-05234. Retrieved from https://rethinkthc.com/research/couttas-2024-dosedependent-effects-of-oral
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.